Key Stats for IQV Stock
- This Week’s Performance: 6%
- 52-Week Range: $136 to $247
- Valuation Model Target Price: around $230
- Implied Upside: 28%
Analyze your favorite stocks like IQVIA Holdings with TIKR (It’s free) >>>
What Happened?
IQVIA Holdings Inc. stock rose about 6% this week, finishing near $181 per share as investors reassessed one of the biggest debates around the company: whether AI is a threat to clinical research outsourcing or a tool that can make IQVIA more valuable to drugmakers. IQVIA provides clinical research services, healthcare data, analytics, and commercial tools for pharmaceutical companies, so the stock is being compared with CRO and healthcare services peers such as ICON, Medpace, Labcorp, Thermo Fisher, and Charles River Laboratories as investors look for the companies best positioned for a recovery in drug development spending.
The stock moved higher because IQVIA’s recent Q1 results showed stronger revenue, raised EPS guidance, solid R&D bookings, and more buyback support, giving investors a clearer reason to buy the rebound. Revenue rose 8.4% year over year to $4.15 billion, adjusted EBITDA reached $932 million, and adjusted diluted EPS came in at $2.90, while management reaffirmed full-year 2026 revenue guidance of $17.15 billion to $17.35 billion and raised adjusted diluted EPS guidance to $12.65 to $12.95. The company also repurchased $552 million of stock in Q1 and later received board approval for a $2 billion increase to its share repurchase authorization, bringing total remaining authorization to about $3.2 billion.
At the Bank of America Global Healthcare Conference after the Q1 report, IQVIA CFO Michael Fedock said the company started the year with revenue and EPS above the high end of expectations, with Commercial Solutions organic revenue growth accelerating 2x versus the prior year and RDS organic revenue growth accelerating more than 3x. He highlighted about $2.5 billion in RDS net bookings, double-digit year-over-year bookings growth, and a 1.04 book-to-bill ratio, while saying AI fears are becoming more of a tailwind as clients adopt IQVIA’s data and AI agent tools. Fedock said, “AI has already been embedded in almost everything that we do,” and noted that 19 of the top 20 pharma companies are already using IQVIA agents, with more than 500 agents expected in production by the end of 2027.
Analyst actions also helped frame the recovery. TD Cowen upgraded IQVIA to Buy from Hold and raised its price target to $213 from $174, while Barclays upgraded the stock to Overweight with a $210 target, showing that some analysts are becoming more constructive after AI and CRO demand concerns pressured the stock earlier this year. That matters because IQVIA’s edge comes from combining clinical trial services with large healthcare datasets and software tools, which could help it win more work if pharma customers keep using AI to speed up drug development rather than cut outsourcing budgets.
Value IQVIA Holdings instantly (Free with TIKR) >>>
Is IQV Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth: around 6%
- Operating Margins: around 17%
- Exit P/E Multiple: 14x
IQVIA’s valuation case depends on whether the company can convert its large R&D backlog into revenue while keeping Commercial Solutions growing through analytics, consulting, patient solutions, and AI-enabled tools.
Analyst estimates point to revenue rising from about $16 billion in 2025 to about $22 billion by 2030, which means IQVIA does not need explosive growth for the stock to work.
See analysts’ growth forecasts and price targets for IQVIA Holdings (It’s free) >>>
The key business drivers over the next 12 months are backlog conversion, stronger emerging biotech funding, continued demand from large pharmaceutical customers, and better productivity from IQVIA’s healthcare data and AI platforms.
Margin recovery also matters because IQVIA carries meaningful debt, so stronger free cash flow can support buybacks, deleveraging, and better per-share earnings growth.
At current levels, IQVIA appears undervalued, with the model estimating a target price around $230 and about 28% total upside, driven by steadier revenue growth, improving earnings visibility, and stronger execution across R&D Solutions and Commercial Solutions.
How Much Upside Does IQV Stock Have From Here?
Investors can estimate IQVIA Holdings’ potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
Value IQVIA Holdings in under 60 seconds with TIKR (It’s free) >>>
